Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures

Phase 2

Terminated

• Conditions: Childhood Absence Epilepsy
• Interventions: Drug: Cannabidiol Oral Solution

• Registration Number: NCT03355300
• Lead Sponsor: Radius Pharmaceuticals, Inc.

Brief Summary

The primary purpose of this study is to assess the long-term safety and tolerability of Cannabidiol Oral Solution (CBD) in pediatric participants with treatment-resistant childhood absence seizures.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2017-11-09
• Study First Submitted QC: 2017-11-21
• Study First Posted: 2017-11-28
• Study Start: 2018-02-20
• Primary Completion: 2019-06-24
• Study Completion: 2019-06-28
• Results First Submitted: 2022-11-23
• Status Verified: 2023-05
• Results First Submitted QC: 2023-05-24
• Last Update Submitted: 2023-05-24
• Results First Posted: 2023-06-18
• Last Update Posted: 2023-06-18

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 11

Inclusion Criteria

1. Completed all activities through Visit 6 (End of Study) of INS011-17-103.
2. Participant and/or parent(s)/caregiver(s) fully comprehend the informed consent form (ICF) and assent form, understand all study procedures, and can communicate satisfactorily with the investigator and study coordinator, in accordance with applicable laws, regulations, and local requirements.
3. A female participant is eligible to participate in the study if she is premenarchal, or of childbearing potential with a negative urine pregnancy test at the Screening Visit. If sexually active, she must agree to either complete abstinence from intercourse or use acceptable methods of contraception throughout the study and for 4 weeks after completion of study participation or discontinuation from investigational product.
4. A sexually active male participant or partner of enrolled participant must be willing to use acceptable methods of contraception throughout the study and for 4 weeks after completion of study participation or discontinuation from investigational product.
5. In the opinion of the investigator, the parent(s)/caregiver(s) is (are) willing and able to comply with the study procedures and visit schedules, including venipuncture, and the visit schedules.

Read More

Exclusion Criteria

1. Participant or parent(s)/caregiver(s) have daily commitments during the study duration that would interfere with attending all study visits.
2. Experienced an anoxic episode related to study drug requiring resuscitation during their previous study.
3. Developed an adverse event thought to be related to CBD in the previous study and for whom the Investigator determines that continuing treatment with CBD would not be in the best interest of the participant.
4. Evidence of other clinically significant disease such as unstable hepatic, hematological, renal, cardiovascular, gastrointestinal, immunological, or pulmonary diseases or ongoing malignancies.
5. Compromised respiratory function or severe respiratory insufficiency.
6. Clinically significant abnormal laboratory values within the past 14 days.
7. In the opinion of the investigator, the participant is unsuitable in any other way to participate in this study.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Cannabidiol Oral Solution	Cannabidiol Oral Solution	Cannabidiol Oral solution, dose as assigned in INS-17-103.

Primary Outcome Measures

Name	Time	Method
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)	Baseline (Visit 6 of INS011-17-103) and Visit 10 (up to approximately 54 weeks)	An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product during the course of a clinical investigation. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product, whether or not thought to be related to the investigational product. An SAE is any untoward medical occurrence that results in death, is life-threatening, requires the participant be at a risk of death at the time of the event, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital abnormality/birth defect, or other serious event that requires medical or surgical intervention. A summary of SAEs and all other non-serious AEs, regardless of causality, is located in the Reported AEs module.

Trial Locations

Locations (9)

Akron Children's Hospital; 🇺🇸 Akron, Ohio, United States

Children's Hospital of Philadelphia; 🇺🇸 Philadelphia, Pennsylvania, United States

Nicklaus Children's Hospital; 🇺🇸 Miami, Florida, United States

Pediatric Epilepsy and Neurology Specialists; 🇺🇸 Tampa, Florida, United States

Primary Children's Hospital; 🇺🇸 Salt Lake City, Utah, United States

Children's Specialty Group, Division of Child & Adolescent Neurology; 🇺🇸 Norfolk, Virginia, United States

Institute for Research and Innovation | MultiCare Health System; 🇺🇸 Tacoma, Washington, United States

Clinical Integrative Research Center of Atlanta; 🇺🇸 Atlanta, Georgia, United States

Oregon Health and Science University; 🇺🇸 Portland, Oregon, United States